Allergic asthma is an inflammatory pulmonary disease associated with aberrant innate and adaptive immune responses to allergens. The key clinical features of the disease are underpinned by mucus hypersecretion, inflammatory infiltrates, and airway hyperreactivity. Asthma is typically characterized by T H 2 responses and their related secreted cytokines, namely IL-4, IL-5, and IL-13.
1 Asthma in human subjects is induced by several allergens, such as innocuous antigens, including birch pollen, and protease antigens, such as papain, Alternaria alternata, or house dust mite (HDM). Mouse models of allergic asthma are induced by either protease allergens or ovalbumin (OVA) after systemic priming.
HDM contains several antigens with protease activity and plays an important role in initiating, as well as sustaining, inflammation through induction of T H 2 and IgE responses. [2] [3] [4] HDM causes epithelial barrier dysfunction with disruption of tight junctions and production of proinflammatory cytokines and modulates function of various cell types, including T H 2 responses. 3, [5] [6] [7] [8] [9] [10] The interactions between naive T lymphocytes and antigen-presenting cells mediated by the contact between the peptides MHC class II and T-cell receptor (TCR), as well as by costimulatory molecules, such as CD28, 11 allow formation of an immunologic synapse that comprises protein kinase C theta (PKC-u). 12 PKC-u recruitment into the immunologic synapse is required for full effector T-lymphocyte activation. 13 PKC-u regulates T-cell activation in several inflammatory disease models, such as allergic asthma, multiple sclerosis, arthritis, and inflammatory bowel disease.
11,14 PKC-u is critical for the activation of several transcription factors, such as nuclear factor kB, nuclear factor of activated T cells (NFAT), c-Jun, c-Fos, and activator protein 1, 15 and also promotes the development of regulatory T (Treg) cells by enhancing forkhead box P3 (FoxP3) expression through activation of the calcineurin/NFAT pathway. 16 More recently, type 2 innate lymphoid cells (ILC2s) have been identified as a critical source for the production of early T H 2-type cytokines, including IL-5 and IL-13. 17, 18 Although the role of PKC-u has been explored in T H 2 cells, its contribution to ILC2 activation remains unclear.
Herein we demonstrate that PKC-u is critical for ILC2 activation and contributes to the acquisition of T H 2 cell effector functions. We demonstrate that PKC-u is expressed in both human and mouse ILC2s and that its deletion decreases the emergence and activation of ILC2s followed by a reduced T H 2 cell response, which is associated with reduced NFAT1 and interferon regulatory factor 4 (IRF4) expression. Importantly, adoptive transfer of ILC2 restores eosinophil influx and production of the T H 2 cytokines IL-4, IL-5, and IL-13 in the lung. Pharmacologic inhibition of PKC-u by a specific PKC-u inhibitor (Compound 20 [C20]/BIX02656; Boehringer Ingelheim, Indianapolis, Ind) markedly reduced the number and activation of ILC2s and cardinal features of allergic lung inflammation induced by HDM.
METHODS Animals
PKC-u-deficient mice on the C57BL/6 background (7-8 weeks old) were generated by the Littman Lab 19 and obtained from Manfred Kopf (Molecular Biomedicine, ETH Z€ urich, Switzerland), and Rag2 2/2 Ly5.1 mice were obtained from Benedita Rocha (INEM; Necker Institute, Inserm U1151-CNRS UMR 8253, Paris, France). 20 Both PKC-u-deficient and littermate wild-type (WT) control mice on the C57BL/6 background were bred in the Transgenose Institute animal facility (TAAM; UPS44 CNRS, Orleans, France). All animals were maintained according to Federation for Laboratory Animal Science Associations regulations, which complied with the French government's ethical and animal experiment regulations. Mice were maintained in a temperature-controlled (238C) facility with a strict 12-hour light/dark cycle, and food and water were provided ad libitum. Experiments were performed with sex-matched mice aged 8 to 10 weeks. All protocols were approved by the CNRS institutional animal research ethics committee under number CLE CCO 2013-1004.
Human PBMCs and sorting of ILC subsets and subsequent gene expression analysis Blood samples from healthy volunteers were collected by the French blood bank (French Blood Institute; EFS, Rungis, France) after approval of the study protocol by an ethics committee (no. #12/R/129). Human PBMCs were isolated by means of density gradient centrifugation (Ficoll; Eurobio, Les Ulis, France) from buffy coats. ILC subsets were isolated as described in the Methods section in this article's Online Repository at www.jacionline.org.
HDM-induced allergic airway inflammation induction
Twice daily (days 0 and 7) intranasal administration of 25 mg of HDM (Dermatophagoides pteronyssinus) extracts (ALK-Abell o, Hørsholm, Denmark) without adjuvant were made in isoflurane-anesthetized mice to induce HDMdriven eosinophilic airway inflammation. Control mice were challenged with saline alone and were challenged on days 14 to 16 with 5 mg of HDM extracts.
Twenty-four hours after the last challenge, airway hyperreactivity was measured, and mice were killed. Bronchoalveolar lavage fluid (BALF) and lung tissue were collected for eosinophil peroxidase (EPO) enzyme, cytokine, and chemokine measurement; histology; quantitative real-time PCR; and Western blot analysis.
Inhibition of PKC-u in vivo with C20
To inhibit PKC-u in vivo, during challenge from days 14 to 16, mice received 10 mg/kg PKC-u selective inhibitor C20 through the oral route, as described previously. 13 
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed by washing the lungs 4 times with 0.5 mL of saline solution at room temperature. After centrifugation at 400g for 10 minutes at 48C, the supernatant (cell-free BAL fluid) was stored at 2208C for cytokine analysis. Fluorescence-activated cell sorting (FACS) analysis on BAL fluid and lung mononuclear cells was performed.
Pulmonary EPO activity
EPO activity was determined to estimate the recruitment of eosinophils to the lung parenchyma, as previously described. 21 
Determination of bronchial hyperresponsiveness
For invasive measurement of dynamic resistance, mice were anesthetized with intraperitoneal injection of a solution containing ketamine (100 mg/kg; Merial, Duluth, Ga) and xylazine (10 mg/kg; Bayer, Robinson Township, Pa), paralyzed with D-tubocuranine (0.125%; Sigma, St Louis, Mo), and intubated with an 18-gauge catheter. Respiratory frequency was set at 140 breaths/min with a tidal volume of 0.2 mL and a positive end-expiratory pressure of 2 mL H 2 O. Increasing concentrations of aerosolized methacholine (9.375, 18.75, 37.5, 75, and 150 mg/mL) were administered. Resistance was recorded with an invasive plethysmograph (Buxco, London, United Kingdom). Baseline resistance was restored before administering the subsequent doses of methacholine.
ILC2 expansion, isolation, and adoptive cell transfer
Mice were anesthetized with isoflurane (3%) and treated with recombinant IL-33 (1 mg per mouse; Ser109-Ile266; obtained from Jean Philippe Girard laboratory, CNRS-Institute of Pharmacology and Structural Biology IPBS, Toulouse, France) daily for 5 days, as described previously.
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J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 5 Briefly, lungs were harvested after perfusion on day 6 and digested in 125 mg/mL Liberase TL and 1 mg/mL DNAse 1 (Roche Diagnostics, Mannheim, Germany). Nonadherent cells were stained for ST2-fluorescein isothiocyanate (clone DJ8, MD Biosciences, Zurich, Switzerland), lineage markers (B220, FcεRI, CD11b, CD3ε, and Siglec-F) labeled with phycoerythrin (PE), inducible costimulator-PECy7 (clone 7E-17G9; eBioscience, San Diego, Calif), and CD45-allophycocyanin (clone 30-F11, eBioscience), and ILC2s were sorted with a MoFlo (Beckman Coulter, Fort Collins, Colo).
Expression of IL-5, IL-13, and IRF4 was detected by means of intracellular/intranuclear staining with anti-IL-5-PE (clone TRFK5; BD Biosciences, San Jose, Calif) or anti-IL-13-allophycocyanin (clone ebio13A, eBioscience), anti-IRF4-allophycocyanin (clone REA201; Miltenyi Biotec, Bergisch Gladbach, Germany) after activation with phorbol 12-myristate 13-acetate (50 ng/mL) and ionomycin (750 ng/mL) in the presence of Brefeldin A (1 mL/1 3 10 6 cells, BD Biosciences) and cell permeabilization (BD Cytofix/Cytoperm, BD Biosciences).
Sorted lung ILC2s (10 4 cells per well) were expanded in vitro in 96-well round-bottom plate in 10% (vol/vol) FBS RPMI complete medium containing IL-2 (10 ng/mL) and IL-33 (10 ng/mL) for 5 days, as described previously. 23 The medium was removed, and fresh medium or recombinant mouse IL-33 (100 ng/mL) was added for 4 hours, followed by RNA extraction.
For ILC2 transfer, 1 3 10 5 ILC2s in 50 mL of PBS were inoculated intratracheally at day 0, followed by HDM (25 mg per mouse) challenge at days 1 and 5 to 7 to WT and PKC-u mice after achievement of isoflurane (3%) anesthesia. Mice were killed at day 8, BAL was performed in some experiments to assess lung inflammation, and FACS analysis was performed.
In some experiments lung mononuclear cells were isolated in whole lungs. ILC2 proliferation was detected with Ki-67 staining (BV421-labeled anti-mouse Ki-67, clone 16A8; BioLegend, San Diego, Calif).
Lung mononuclear cell isolation and stimulation
Lung mononuclear cells were isolated from WT and PKC-u-deficient (PKC-u 2/2 ) mice 24 hours after the last challenge, as described previously. 24 Briefly, the aorta and inferior vena cava were sectioned, and the lungs were perfused with saline. The lobes of the lungs were sliced into small cubes and then incubated for 45 minutes in 2 mL of RPMI 1640 solution and digested in 125 mg/mL Liberase TL and 1 mg/mL DNAse 1 (Roche Diagnostics). Isolated lung mononuclear single cells were plated in round-bottom 96-well plates (2 3 10 6 /mL) and restimulated for 4 hours in vitro with phorbol 12-myristate 13-acetate (50 ng/mL) and ionomycin (750 ng/mL, both from Sigma-Aldrich) in the presence of Brefeldin A (1 mL/1 3 10 6 cells, BD Biosciences) for intracellular flow cytometric analysis. Lung mononuclear cells (1 3 10 6 cells) were restimulated either with anti-CD3e/CD28 (3 mg/mL, respectively) or HDM (100 mg/mL) in a 96-well plate for 3 days. Supernatants were analyzed for the presence of cytokines by using the Multiplex immunoassay (MagPix; Bio-Rad Laboratories, Hercules, Calif).
Flow cytometric analysis on BAL cells
Single-cell suspensions were prepared from BAL fluid after blockade of Fc receptors with CD16/CD32 blocking antibody. Cells were stained with antibodies in FACS buffer (D-PBS, containing 3% heat-inactivated FCS and 0.005% NaN 3 ) for 30 minutes with allophycocyanin-conjugated anti-I-Ad/IEd (macrophages/dendritic cells [DCs]), PE-conjugated anti-Siglec-F (clone E50-2440; eosinophils), fluorescein isothiocyanate-conjugated anti-CD3 (clone 145-2C11) and anti-CD45R/B220 (clone RA5-6B2; lymphocytes), and eFluor 450-conjugated anti-F4/80 (clone BM8) and biotin-conjugated anti-CD11c (clone HL3; macrophages/DCs). Differential cell counts were analyzed by using flow cytometry and cytospins, as previously described. 25 Data were acquired with the FACSCanto II flow cytometer and analyzed with Diva and FlowJo software (TreeStar, Ashland, Ore).
Lung histology
Lungs were fixed in 4% buffered formaldehyde, and 3-mm sections were stained with periodic acid-Schiff (PAS) reagent and examined with a Leica DM2500 microscope (340 magnification; Leica, Wetzlar, Germany).
Peribronchial infiltrates and mucus hypersecretion were assessed by using a semiquantitative score (0-5) by 2 observers independently, as described previously. 21 Cytokine and chemokine measurement by means of ELISA IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-13, IL-33, CXCL1 (keratinocyte chemoattractant), CCL11 (eotaxin), CCL17 (thymus and activationregulated kinase), CCL20, CCL22 (macrophage-derived chemokine), and CCL24 (eotaxin-2) concentrations in cell-culture supernatants from restimulated lung mononuclear cells and lung homogenates were determined by means of ELISA with commercial kits from R&D Systems (Abingdon, United Kingdom), according to the manufacturer's recommendations, or by using the multiplex immunoassay with a MagPix reader (Bio-Rad Laboratories).
Immunoblotting of NFAT1
Lung tissues were homogenized in Tris-HCl 0.05M (pH 8) with Polytron PT 2100 (Kinematica AG, Luzern, Switzerland). Protein concentration was determined by using the Bradford method (Bio-Rad Laboratories). Equal amounts of protein (30 mg per sample) were denaturated by means of boiling (958C for 5 minutes), separated by using SDS-PAGE, and transferred to nitrocellulose membranes (GE Healthcare, Fairfield, Conn). The membrane was blocked in Trisbuffered saline and Tween 20 containing 5% lipid-free dry milk. Antibodies used for detection were diluted in Tris-buffered saline and Tween 20 containing 5% lipid-free dry milk and were from Sigma, unless otherwise stated.
The control b-actin was detected with primary mouse anti-b-actin antibody, followed by the biotinylated secondary antibody horseradish peroxidaseconjugated goat anti-mouse immunoglobulin. NFAT1 (NFATc2) was detected with primary polyclonal anti-mouse NFAT1 (Cell Signaling, Danvers, Mass), followed by the secondary antibody horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin (Cell Signaling). Immunoreactive bands were visualized with an enhanced chemiluminescence kit (GE Healthcare).
RNA isolation and quantitative RT-PCR
Lung lobes were transferred in RNAlater solution for 24 hours at 48C and snap-frozen in liquid nitrogen. Total RNA was isolated from homogenized mouse lung or ILC2-sorted cells by using TRI Reagent (Sigma) and quantified by using NanoDrop (Nd-1000). Reverse transcription was performed with the SuperScript III Kit, according to the manufacturer's instructions (Invitrogen, Carlsbad, Calif). cDNA was subjected to quantitative PCR by using primers for mouse Muc5ac (forward: 5'CAGCCGAGAGGAGGGTTTGATCTand reverse: 5'AGTCTCTCTCCGCTCCTCTCA; Sigma), Gata3 (QT00170828), Il4 (QT00160678), Il5 (QT00099715), Il13 (QT00099554), Irf4 (QT00109984), Rn18s (QT02448075), and Il1rl1 (QT01063062) from Qiagen (Hilden, Germany). Relative transcript expression of a gene is given as 2 2DDCt . For ILC2 analysis, mRNA expression was assessed by using b-actin or RN18s for human and mouse samples, respectively, as endogenous controls. The relative amount of target genes in each sample was calculated in comparison with a calibrator sample (type 1 innate lymphoid cells [ILC1s]) for human samples and naive primary mouse tracheal epithelial cells or naive lymph node cells for mouse samples.
Statistical analysis
A Mann-Whitney U analysis and nonparametric Kruskal-Wallis test followed by the Dunn posttest were used to determine significant differences between groups by using GraphPad Prism software (version 5.00; GraphPad Software, La Jolla, Calif). Data are expressed as means 6 SEMs.
RESULTS

Increased PKC-u gene expression in human and mouse ILC2s
To determine whether PKC-u has a role in ILC2s, we assessed PKC-u expression in human ILC subsets isolated from human PBMCs and mouse ILC2 populations purified from the lung (see Fig E1, gating strategy, in this article's Online Repository at www. jacionline.org). We observed significant expression of the Prkcq and Gata3 genes in ILC2s compared with ILC1 and type 3 innate lymphoid cell (ILC3) subsets (Fig 1, A) . Purified mouse lung ILC2s from WT mice showed a significant induction of Prkcq transcript (Fig 1, B) compared with primary mouse tracheal epithelial cells, which express low levels of Prkcq. IL-33 restimulation did not further increase Prkcq gene levels. To investigate whether isolated ILC2s are functional, we assessed T H 2-associated gene expression on ILC2s (IL4, IL5, IL13, Il1rl1 (ST2), Gata3, and Irf4) by using quantitative RT-PCR analysis. Values are the means 6 SEMSs. LN, Lymph node; n.s., not significant. *P < .05, **P < .01, and ***P < .001.
Lung ILC2s upregulated the expression of numerous T H 2-associated genes, such as IL4, IL5, IL13, Il1rl1 (ST2), and Gata3, in comparison with naive lymph node cells (Fig 1, C) . IL-33 restimulation did not further increase IL4, IL5, IL13, Il1rl1 (ST2), and Gata3 gene levels. However, Irf4 was downregulated in ILC2s when compared with naive lymph node cells (Fig  1, D) . Therefore the PRKCQ gene is expressed in both human and mouse functional ILC2 populations.
Reduced innate lymphoid cell activation in PKC-u 2/2 mice ILC2s accumulate in lungs shortly after allergen exposure and produce IL-5 and IL-13.
26 PKC-u 2/2 mice or littermate WT control mice were immunized with HDM (25 mg administered through the intranasal route at days 0 and 7), followed by 3 intranasal challenges (5 mg of HDM on days [14] [15] [16] , to determine the relative contribution of PKC-u signaling on lung ILC2 activation (Fig 2, A) . Twenty-four hours after the last HDM challenge, total, IL-5-producing, and IL-13-producing ILC2s were analyzed. Frequencies and total counts of ILC2 (Fig 2, B-F) . These data indicate that PKC-u signaling is required for ILC2 activation and production of IL-5 and IL-13. We then asked whether the inhibitory effect correlated with a diminished adaptive T H 2 response.
PKC-u
2/2 mice have reduced airway eosinophilia and T H 2-driven airway inflammation T H 2 cells drive the adaptive immune response in allergic airway inflammation, and PKC-u has been shown to be important for the response to OVA. 11, 27 WT or PKC-u 2/2 mice were treated as reported in Fig 2, A, and BAL was performed for inflammatory cell counts to determine whether PKC-u is also involved in airway Representative data of 2 independent experiments are presented (n 5 4 for the saline control group and n 5 8 for the HDM group). FSC, Forward scatter; ICOS, inducible costimulator; SSC, side scatter. Values are means 6 SEMs. *P < .05, **P < .01, and ***P < .001.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 5 inflammation induced by the complex and relevant allergens, such as HDM extracts. Saline-sensitized and challenged WT and PKC-u 2/2 mice were used as negative controls and did not exhibit any inflammatory response, as evidenced by the negligible number of leukocytes in the BALF. However, WT mice, which were HDM sensitized and challenged, had a dramatic increase in total leukocyte numbers in BALF (Fig 3, A) . The predominant cell infiltrate in BALF consisted of eosinophils and EPO activity in the lung (Fig 3, B and C) , with lower lymphocyte counts (Fig 3, D) . In striking contrast, HDM-primed PKC-u 2/2 (PKC-u 2/2 HDM) mice exhibited 3-fold lower total leukocyte counts in BALF compared with their WT counterparts (Fig 3, A) . In particular, there was a significant decrease in eosinophilia (3-fold reduction; Fig 3, B and C) , as well as a lower lymphocyte count (2-fold reduction compared with WT-HDM; Fig 3, D) .
A hallmark of allergic lung inflammation is airway resistance, which was measured by using invasive plethysmography in WT and PKC-u 2/2 mice. Of note, PKC-u 2/2 mice treated with HDM had reduced airway resistance compared with WT mice (Fig 3, E) .
Histologic analysis revealed a prominent lung inflammatory response characterized by perivascular and peribronchiolar infiltration of eosinophils and mononuclear cells in WT-HDM mice (Fig 3, F) . By contrast, a significant reduction of inflammatory cell infiltration was found in PKC-u 2/2 mice, which is consistent with reduced cell counts in BALF (Fig 3,  G) . Additionally, the extensive goblet cell hyperplasia and mucus production observed in primed and challenged WT mice was reduced in PKC-u 2/2 mice because approximately 80% of goblet cells stained strongly with PAS in WT mice versus only approximately 10% to 20% in PKC-u 2/2 mice (Fig 3, H) . The reduced mucus overproduction was confirmed at the mRNA expression level for Muc5ac in lung (Fig 3, I) .
Moreover, levels of proinflammatory and T H 2 cytokines, such as IL-1a, IL-1b, IL-4, IL-5, and IL-13, were significantly reduced (2-to 3-fold reduction) in lungs of PKC-u 2/2 HDM mice compared with those of WT-HDM mice (Fig 4, A, B, and D-F) . By contrast, IL-33 levels were unchanged in the absence of PKC-u (Fig 4, C) .
We further investigated T H 2 cell numbers in the lungs in HDM-challenged mice and found an increase in the numbers of In addition, in the absence of PKC-u, significantly lower levels of the neutrophil/monocyte-attracting chemokine CXCL1 (2-fold reduction), basophils, and the eosinophil-attracting chemokines CCL11 and CCL24 (2-fold reduction), as well as the T H 2 cell-attracting chemokines CCL17 and CCL20 (approximately 2-fold reduction), were found in the lungs compared with those in WT-HDM mice (Fig 4, G-K) .
Taken together, these data indicate an important role of PKC-u in the initiation of airway allergic inflammation to HDM.
PKC-u deletion reduces IRF4 and NFAT1 expression and determines lung T H 2 cell numbers and activation
The transcription factors IRF4 and NFAT1 are known to promote T H 2 cell differentiation and function, including IL-4 and IL-5 expression, and contribute to IL-10 production. [28] [29] [30] To analyze the transcription factors involved in the PKC-u phenotype on HDM exposure, we investigated IRF4 expression by using quantitative PCR (Fig 4, L) and the expression of NFAT1 (NFATC2) by using Western Blot analysis in lung tissues (Fig  4, M) . We found a distinct reduction of these transcription factors in the lungs of PKC-u 2/2 mice. Therefore the data suggest that a lack of PKC-u is associated with decreased expression of NFAT1 and IRF4.
We investigated whether numbers and activation of CD45 
CD3ε
1 population was reduced, and T cells have a reduced expression of the activation marker CD69 (see Fig E3, B and D, in this article's Online Repository at www.jacionline.org). Because Treg cells can contribute to the overall response to the allergen HDM, we determined pulmonary Treg cell numbers and found a significant reduction in number of FoxP3 cells in the absence of PKC-u (see Fig E3, E-G) . PKC-u is expressed in natural killer (NK) cells and was found to be important for tumor growth control, IFN-g and TNF-a production, and NKT cell function. [31] [32] [33] To determine whether PKC-u is involved in NKp46 cell counts, we isolated mononuclear cells from the lungs of PKC-u 2/2 versus WT mice after HDM challenge. Similar CD45 Collectively, these data demonstrate that PKC-u is important for the activation of T H 2 responses and FoxP3
1 Treg cell recruitment.
PKC-u 2/2 antigen-presenting cells process the allergen but cannot activate T cells in vitro
To exclude any effect on antigen uptake and processing, we investigated these parameters in bone marrow-derived dendritic cells (BMDCs) using OVA as an antigen. The uptake and processing in PKC-u 2/2 BMDCs was not different from those in WT BMDCs (see Fig E5, A and B, in this article's Online Repository at www.jacionline.org). However, PKC-u 2/2 BMDCs showed reduced MHC class II expression (see Fig E5, C) . We further analyzed the ability of BMDCs to produce proinflammatory cytokines on HDM activation and found Values are means 6 SEMs. *P < .05, **P < .01, and ***P < .001.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 5 reduced IL-1a production (see Fig E5, D) , whereas IL-1b and IL-10 production were not affected (see Fig E5, E and F) . Coculture of WT-BMDCs primed with HDM with naive CD4
1 T cells induced a robust cell proliferation of carboxyfluorescein succinimidyl ester-labeled T cells and IL-2 production, which was dramatically reduced when cocultured with PKC-u 2/2 CD4 1 T cells (see Fig E5, G and H). Therefore PKC-u 2/2 CD4 1 T cells are unable to proliferate to HDM in vitro. The lack of response in PKC-u 2/2 mice might be at the T-cell and DC level because of reduced IRF4 expression because DC activation relies on IRF4 expression. 34 Consistent with published data, PKC-u
T cells do not respond to TCR activation by CD3ε antibody (see Fig E5, I) . The data reveal diminished T-cell and DC activation, as reported previously.
Adoptive transfer of ILC2s in PKC-u 2/2 mice restores lung inflammation and T H 2 cytokine production IL-33 is known to be an important cytokine for the promotion of ILC2 expansion. 17, 35 To address whether PKC-u signaling affected the fate of ILC2s, we treated WT and PKC-u 2/2 mice with recombinant IL-33 for 5 days. We observed a significant increase in ILC2 counts in WT mice. In contrast, the percentage and number of ILC2s were greatly reduced in PKC-u 2/2 ( Fig 5, A and  B) . Thus PKC-u plays an important role in ILC2 induction.
To test whether the role of ILC2s in HDM-induced airway inflammation is dependent on PKC-u signaling, we adoptively transferred purified ILC2s from either WT or Rag2 Mice were challenged 4 times at days 1 and 5 to 7 with HDM extract and analyzed 24 hours after the last HDM challenge. The ILC2 transfer and HDM challenge led to increased lung inflammation compared with ILC2 transfer alone in WT mice (3-fold increase; Fig 5, C-E, and see Fig E6, B) .
To determine whether transferred ILC2s have the ability to proliferate, we used Ki-67 as a surrogate marker of proliferation and found a high ILC2 
Ki-67
1 cell population in the lung after HDM administration in WT mice. However, ILC2 proliferation was reduced in PKC-u 2/2 compared with WT mice. In addition, the transferred ILC2 1 (ILC2 1 CD45.1 1 ) cells proliferated and restored the low proliferation seen in PKC-u 2/2 mice (see Fig E6, F and G, and Fig E7, G-M, in this article's Online Repository at www.jacionline.org). The transferred ILC2s also produced both IL-5 and IL-13 (see Fig E7, N, and data not shown) .
We investigated T H 2 cells within the lung after ILC2 adoptive transfer and found an increased number of TCRb 1 CD4 1 cells expressing IL-5 (see Fig E6, H) and IL-13 (see Fig E6, I ) in WT mice after HDM administration. In the absence of PKC-u, the numbers of TCRb 
CD4
1 cell populations. These changes were accompanied by increased T H 2 cytokine and chemokine (IL-4, IL-5, IL-13, CCL17, and CCL24) production in cell-culture supernatants from lung mononuclear cells after HDM restimulation in WT mice (Fig 5, F-H , and see Fig E6, C) . Interestingly, ILC2 transfer and HDM challenge to PKC-u 2/2 mice restored lung inflammation, including total leukocyte, eosinophil, and lymphocyte counts in BALF (Fig 5, D and F) and IL-4, IL-5, IL-13, CCL17, and CCL24 ns, Not significant. *P < .05, **P < .01, and ***P < .001. n.s., Not significant. *P < .05, **P < .01, and ***P < .001.
production in culture supernatants from lung mononuclear cells (Fig 5, G-K , and see Fig E6, C) . Therefore PKC-u signaling is critical for ILC2 expansion and activation and potentially mediated T H 2-driven allergic airway inflammation.
PKC inhibitor (C20) reduces HDM-induced ongoing allergic asthma
To determine the mechanism that might account for the suppressed allergic phenotype in response to PKC-u signaling during the effector phase in the allergic response to HDM, we J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 5 investigated the effect of the specific inhibitor of PKC-u C20 (BIX02656), which was shown to inhibit PKC-u in vitro.
13
Sensitized WT mice were treated orally with PKC-u inhibitor at doses of 10 mg/kg for 3 days during HDM challenge on days 14 to 16, as described in Fig 6, A. At day 14, before starting C20 treatment, we have checked whether lung inflammation is already established in WT mice. At day 14, after 2 HDM immunizations, WT mice exhibited strong lung inflammation, as evidenced by increased eosinophil and lymphocyte recruitment in the bronchoalveolar space (BALF), Muc5ac gene expression in lung tissue, and IL-13, IL-33, CCL17, and CCL24 production in lung homogenates after anti-CD3ε or HDM restimulation (see Fig  E8 in this article's Online Repository at www.jacionline.org). C20 treatment yielded a significant inhibition (2-to 3-fold reduction) of eosinophils and lymphocytes in the airways (Fig 6, B-E) , with a significant reduction in HDM-induced increase in airway resistance (Fig 6, F) and reduced ILC2 numbers; ILC2s expressing IL-5, IL-13, and IRF4 levels; airway inflammation; and mucus overproduction, as evidenced by histologic analysis and mRNA expression levels for Muc5ac (Fig 6, G-K Moreover, IRF4 expression from pulmonary tissue was reduced, as well as NFAT1 production in the lung (Fig 6, S and T) . Importantly, pulmonary cells produced similar amounts of IL-33 in response to HDM immunization either in the presence or absence of PKC-u blockade (Fig 6, N) .
Therefore disruption of the PKC-u signaling pathways with the PKC-u inhibitor C20 inhibits ongoing allergic inflammation and reduces IRF4 and NFAT1 expression.
DISCUSSION
Recent evidence has implicated ILC2s in T H 2 responses. 17, 36 For the first time, we demonstrate that PKC-u is expressed by both human and mouse ILC2 populations and is likely required for efficient T H 2 cell-mediated allergic lung inflammation on challenge with the protease allergen HDM. Reduced ILC2 and T H 2 cell counts and activation are linked to an inability to mount a strong allergic lung inflammatory response with impaired cardinal features of asthma, including airway hyperresponsiveness and T H 2 cytokine and chemokine release, in PKC-u 2/2 mice. This is the first report suggesting that ILC2 activation is dependent on the PKC-u signaling pathway. ILC2s can expand and be activated after local protease allergen administration, including papain, Alternaria alternata, and HDM, 17, 26, 37 and we show that the emergence of ILC2s is inhibited in the absence of PKC-u. This finding is novel, and PKC-u is required for ILC2 activation. ILC2 precedes the T H 2 differentiation, which is drastically reduced in the absence of PKCu. We questioned whether IL-33, which is known to be involved in ILC2 activation, resulting in IL-5 and IL-13 production, is responsible for the lack of response, but we did not find any difference in IL-33 production in lung tissue in PKC-u 2/2 mice. PKC-u is involved in the TCR synapse, and inhibition of PKC-u reduces the T H 2-mediated response. 12 Although previous studies reported PKC-u-dependent OVA-induced lung inflammation, we show here that all features of HDM-induced allergic asthma are dramatically reduced in the absence of PKC-u. 11, 14 IRF4 functions either as a transcriptional activator or repressor depending on DNA-binding sequences, protein-interacting partners, or both. IRF4 interacts with its family members PU.1 or NFAT1 to synergistically enhance transcriptional activity of a variety of genes, including IL-4, in T-cell and T H 2 cell responses. 34 Our study reveals that the decreased IRF4/NFAT1 expression is associated with decreased allergic inflammation to HDM in PKC-u 2/2 mice. Furthermore, we identified that DC functions are PKC-u dependent. Specifically, MHC class II expression is reduced and associated with the inability of HDM-primed PKC-u 2/2 T cells to mediate T-cell proliferation and induce IL-2 production. Thus we confirm that PKC-u 2/2 T cells are unable to respond to TCR stimulation. 12 We report a role of PKC-u on DC activation and suggest that the defect might be at the class II molecule-dependent antigen platform, which could be related to reduced IRF4 expression, as previously shown by the study showing that IRF4 signaling in DC cells controls T H 2 responses. 34 Importantly, it was shown that PKC-u during the CD8 1 T-cell antiviral response can be overcome by activated DCs. 38 Therefore NFAT1 and IRF4 expression in DCs and T cells are likely PKC-u dependent and contribute to allergic response. J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 5 Because the net inflammatory response depends on other factors, we thought that augmented FoxP3 regulatory cells could contribute to reduced allergic response. However, we found reduced FoxP3 cell counts in PKC-u 2/2 lungs. Therefore Treg cells are unlikely to be involved in our model.
Although we demonstrate that PKC-u is required for the allergic response, it was unknown whether PKC-u blockade could interrupt an ongoing inflammatory response and ILC2 activation of sensitized mice. To address this question, we used the PKC-u inhibitor and found that C20 had a potent therapeutic effect on ongoing HDM-induced allergic inflammatory responses with a drastic inhibition of the immune response, lung inflammation, and airway hyperreactivity. This is an important finding, and our data point to an interesting therapeutic strategy by using the inhibitor to decrease allergic responses.
In conclusion, our data suggest that PKC-u contributes to ILC2 activation and T-cell proliferation, both contributing to T H 2 responses in patients with allergic lung inflammation in response to protease allergens. This response is associated with IRF4 and NFAT1 transcription factor expression. Together with the potent inhibition of asthma by the PKCu inhibitor C20 during allergen challenge, our data suggest that PKC-u might be a novel therapeutic target in asthmatic patients.
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Clinical implications: Pharmacologic inhibition of established asthma suggests that PKC-u represents a potent therapeutic target of the allergic response.
